When immune therapy clears cancer, the real question for resectable tumors becomes: Do we still need to resect?
From early-stage to brain metastases, ASCO’s latest melanoma abstracts spotlight the growing power of targeted and immune-based therapies across disease stages.
ctDNA is helping us track what truly matters—real-time, personalized signals that guide smarter decisions in cancer care.
This past weekend was Father’s Day, and I had the joy of spending it the way it should be spent—surrounded by family. We made a full day of it at the new Epic Universe theme park, something we haven’t done in years. Usually, our theme park visits are quick—annual pass holders popping in for a …
Immunotherapy’s success may hinge on what we preserve, not just what we prescribe.
Five groundbreaking trials from the ASCO Plenary are transforming cancer care—ushering in biomarker-led immunotherapy across multiple disease types.
A year of intentional living, two transformative weeks, and the lessons that come from both stepping away and diving back in.
Yesterday was a relatively light clinic day — just seven patients on the schedule — which left me with some unexpected time for the day. I was invited to a dinner at a well-known steakhouse, hosted by a pharmaceutical company. In full disclosure, I do speaker engagements for industry about two to four times a …
News broke today that President Joe Biden has been diagnosed with stage IV (metastatic) prostate cancer. As an oncologist, this is not just a headline—it becomes an important teaching moment for how we evaluate and manage newly diagnosed metastatic prostate cancer. With the public eye now focused, many are likely wondering: what does this diagnosis …
This post was inspired by a recent review in the New England Journal of Medicine — click here to read it. What moved me most was the extraordinary time, effort, and global collaboration it took to transform the outlook for patients with Ph+ ALL. This progress was only possible because of the clinical trials carried …